Acadia Pharmaceuticals Inc. (ACAD)
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth.
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
